HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation

Per Ljungman, Tetsushi Yoshikawa, Katherine N. Ward

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter deals with the four most recently discovered herpesviruses: the human herpesviruses HHV-6A, HHV-6B, HHV-7, and HHV-8 (also called Kaposi sarcoma-associated herpesvirus). Today know that HHV-6B is the virus that causes the majority of the disease associated with HHV-6. Other clinical associations such as bone marrow suppression, pneumonia, and skin rash mimicking acute graft-versus-host disease (GVHD) have been proposed. The importance of HHV-6A, HHV-7, and HHV-8 is less in stem-cell transplant recipients, although cases with likely pathology due to these viruses have been documented. HHV-6B is an important pathogen in HCT patients primarily through its CNS effects.The risk is highest in patients after cord blood (CB) transplantation and this is a group where it would be logical to implement preventive measures. CMX001 is a drug in clinical development that might be a future alternative. Adoptive transfer of HHV-6-specific T cells might also be a possible management strategy.

Original languageEnglish
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
PublisherWiley-Blackwell
Pages1122-1131
Number of pages10
Volume2-2
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Human Herpesvirus 7
Human Herpesvirus 6
Human Herpesvirus 8
Cell Transplantation
Viruses
Adoptive Transfer
Herpesviridae
Graft vs Host Disease
Exanthema
Fetal Blood
Pneumonia
Stem Cells
Transplantation
Bone Marrow
Pathology
T-Lymphocytes
Transplants

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ljungman, P., Yoshikawa, T., & Ward, K. N. (2016). HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition (Vol. 2-2, pp. 1122-1131). Wiley-Blackwell. https://doi.org/10.1002/9781118416426.ch92
Ljungman, Per ; Yoshikawa, Tetsushi ; Ward, Katherine N. / HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2 Wiley-Blackwell, 2016. pp. 1122-1131
@inbook{e388495622ac468888c4e07d08b748c7,
title = "HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation",
abstract = "This chapter deals with the four most recently discovered herpesviruses: the human herpesviruses HHV-6A, HHV-6B, HHV-7, and HHV-8 (also called Kaposi sarcoma-associated herpesvirus). Today know that HHV-6B is the virus that causes the majority of the disease associated with HHV-6. Other clinical associations such as bone marrow suppression, pneumonia, and skin rash mimicking acute graft-versus-host disease (GVHD) have been proposed. The importance of HHV-6A, HHV-7, and HHV-8 is less in stem-cell transplant recipients, although cases with likely pathology due to these viruses have been documented. HHV-6B is an important pathogen in HCT patients primarily through its CNS effects.The risk is highest in patients after cord blood (CB) transplantation and this is a group where it would be logical to implement preventive measures. CMX001 is a drug in clinical development that might be a future alternative. Adoptive transfer of HHV-6-specific T cells might also be a possible management strategy.",
author = "Per Ljungman and Tetsushi Yoshikawa and Ward, {Katherine N.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/9781118416426.ch92",
language = "English",
isbn = "9781118416006",
volume = "2-2",
pages = "1122--1131",
booktitle = "Thomas' Hematopoietic Cell Transplantation",
publisher = "Wiley-Blackwell",
address = "United Kingdom",

}

Ljungman, P, Yoshikawa, T & Ward, KN 2016, HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation. in Thomas' Hematopoietic Cell Transplantation: Fifth Edition. vol. 2-2, Wiley-Blackwell, pp. 1122-1131. https://doi.org/10.1002/9781118416426.ch92

HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation. / Ljungman, Per; Yoshikawa, Tetsushi; Ward, Katherine N.

Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2 Wiley-Blackwell, 2016. p. 1122-1131.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation

AU - Ljungman, Per

AU - Yoshikawa, Tetsushi

AU - Ward, Katherine N.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This chapter deals with the four most recently discovered herpesviruses: the human herpesviruses HHV-6A, HHV-6B, HHV-7, and HHV-8 (also called Kaposi sarcoma-associated herpesvirus). Today know that HHV-6B is the virus that causes the majority of the disease associated with HHV-6. Other clinical associations such as bone marrow suppression, pneumonia, and skin rash mimicking acute graft-versus-host disease (GVHD) have been proposed. The importance of HHV-6A, HHV-7, and HHV-8 is less in stem-cell transplant recipients, although cases with likely pathology due to these viruses have been documented. HHV-6B is an important pathogen in HCT patients primarily through its CNS effects.The risk is highest in patients after cord blood (CB) transplantation and this is a group where it would be logical to implement preventive measures. CMX001 is a drug in clinical development that might be a future alternative. Adoptive transfer of HHV-6-specific T cells might also be a possible management strategy.

AB - This chapter deals with the four most recently discovered herpesviruses: the human herpesviruses HHV-6A, HHV-6B, HHV-7, and HHV-8 (also called Kaposi sarcoma-associated herpesvirus). Today know that HHV-6B is the virus that causes the majority of the disease associated with HHV-6. Other clinical associations such as bone marrow suppression, pneumonia, and skin rash mimicking acute graft-versus-host disease (GVHD) have been proposed. The importance of HHV-6A, HHV-7, and HHV-8 is less in stem-cell transplant recipients, although cases with likely pathology due to these viruses have been documented. HHV-6B is an important pathogen in HCT patients primarily through its CNS effects.The risk is highest in patients after cord blood (CB) transplantation and this is a group where it would be logical to implement preventive measures. CMX001 is a drug in clinical development that might be a future alternative. Adoptive transfer of HHV-6-specific T cells might also be a possible management strategy.

UR - http://www.scopus.com/inward/record.url?scp=84979911642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979911642&partnerID=8YFLogxK

U2 - 10.1002/9781118416426.ch92

DO - 10.1002/9781118416426.ch92

M3 - Chapter

AN - SCOPUS:84979911642

SN - 9781118416006

VL - 2-2

SP - 1122

EP - 1131

BT - Thomas' Hematopoietic Cell Transplantation

PB - Wiley-Blackwell

ER -

Ljungman P, Yoshikawa T, Ward KN. HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2. Wiley-Blackwell. 2016. p. 1122-1131 https://doi.org/10.1002/9781118416426.ch92